Contact
searchSearch
HMP Global

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

RNAi Topic Center

Featured Article

News
RNAi Therapies Offer New Hope for Patients With Hereditary Transthyretin Amyloidosis
11/08/2024
RNA interference (RNAi)-based treatments for hereditary transthyretin amyloidosis (ATTR) have shown remarkable promise, offering new hope for patients with this rare but devastating genetic disorder.
RNA interference (RNAi)-based treatments for hereditary transthyretin amyloidosis (ATTR) have shown remarkable promise, offering new hope for patients with this rare but devastating genetic disorder.
RNA interference (RNAi)-based...
11/08/2024
First Report Managed Care
News
Experts Publish ATTRv Amyloidosis Recommendations for US Clinicians
10/09/2024
Citing a lack of guidance in the United States addressing hereditary transthyretin (ATTRv; v for variant) amyloidosis with polyneuropathy, a group of 7 neurologists with expertise in ATTRv amyloidosis published recommendations for...
Citing a lack of guidance in the United States addressing hereditary transthyretin (ATTRv; v for variant) amyloidosis with polyneuropathy, a group of 7 neurologists with expertise in ATTRv amyloidosis published recommendations for...
Citing a lack of guidance in the...
10/09/2024
First Report Managed Care
News
Treatment Provides Relief for Recurrent Acute Hepatic Porphyria Attacks
03/04/2022
Patients with recurrent attacks of acute hepatic porphyria had fewer attacks and less health care dependency after treatment with a double-stranded small interfering RNA.
Patients with recurrent attacks of acute hepatic porphyria had fewer attacks and less health care dependency after treatment with a double-stranded small interfering RNA.
Patients with recurrent attacks...
03/04/2022
First Report Managed Care
News
Treatment Proves Highly Effective for Primary Hyperoxaluria Type 1
02/17/2022
Eighteen months of follow-up data suggested lumasiran was highly effective in treating a patient with primary hyperoxaluria type 1, a rare genetic disease.
Eighteen months of follow-up data suggested lumasiran was highly effective in treating a patient with primary hyperoxaluria type 1, a rare genetic disease.
Eighteen months of follow-up...
02/17/2022
First Report Managed Care

Newsfeed

News
RNAi Therapies Offer New Hope for Patients With Hereditary Transthyretin Amyloidosis
11/08/2024
RNA interference (RNAi)-based treatments for hereditary transthyretin amyloidosis (ATTR) have shown remarkable promise, offering new hope for patients with this rare but devastating genetic disorder.
RNA interference (RNAi)-based treatments for hereditary transthyretin amyloidosis (ATTR) have shown remarkable promise, offering new hope for patients with this rare but devastating genetic disorder.
RNA interference (RNAi)-based...
11/08/2024
First Report Managed Care
News
Experts Publish ATTRv Amyloidosis Recommendations for US Clinicians
10/09/2024
Citing a lack of guidance in the United States addressing hereditary transthyretin (ATTRv; v for variant) amyloidosis with polyneuropathy, a group of 7 neurologists with expertise in ATTRv amyloidosis published recommendations for...
Citing a lack of guidance in the United States addressing hereditary transthyretin (ATTRv; v for variant) amyloidosis with polyneuropathy, a group of 7 neurologists with expertise in ATTRv amyloidosis published recommendations for...
Citing a lack of guidance in the...
10/09/2024
First Report Managed Care
News
Treatment Provides Relief for Recurrent Acute Hepatic Porphyria Attacks
03/04/2022
Patients with recurrent attacks of acute hepatic porphyria had fewer attacks and less health care dependency after treatment with a double-stranded small interfering RNA.
Patients with recurrent attacks of acute hepatic porphyria had fewer attacks and less health care dependency after treatment with a double-stranded small interfering RNA.
Patients with recurrent attacks...
03/04/2022
First Report Managed Care
News
Treatment Proves Highly Effective for Primary Hyperoxaluria Type 1
02/17/2022
Eighteen months of follow-up data suggested lumasiran was highly effective in treating a patient with primary hyperoxaluria type 1, a rare genetic disease.
Eighteen months of follow-up data suggested lumasiran was highly effective in treating a patient with primary hyperoxaluria type 1, a rare genetic disease.
Eighteen months of follow-up...
02/17/2022
First Report Managed Care
News
Using Deep Learning to Measure MS-Specific Brain Damage Beyond Aging
11/11/2024
A new study published in Neurology aimed to differentiate age-related brain changes from multiple sclerosis (MS)-specific neurodegeneration using MRI.
A new study published in Neurology aimed to differentiate age-related brain changes from multiple sclerosis (MS)-specific neurodegeneration using MRI.
A new study published in...
11/11/2024
First Report Managed Care
News
Adverse Event Data Suggest Selective β1-blockers Pose Asthma Risk
11/11/2024
The risks of asthma and asthma-like adverse events appear to be higher with selective β1-blockers than with nonselective blockers and α- and β-blockers.
The risks of asthma and asthma-like adverse events appear to be higher with selective β1-blockers than with nonselective blockers and α- and β-blockers.
The risks of asthma and...
11/11/2024
First Report Managed Care
News
RNAi Therapies Offer New Hope for Patients With Hereditary Transthyretin Amyloidosis
11/08/2024
RNA interference (RNAi)-based treatments for hereditary transthyretin amyloidosis (ATTR) have shown remarkable promise, offering new hope for patients with this rare but devastating genetic disorder.
RNA interference (RNAi)-based treatments for hereditary transthyretin amyloidosis (ATTR) have shown remarkable promise, offering new hope for patients with this rare but devastating genetic disorder.
RNA interference (RNAi)-based...
11/08/2024
First Report Managed Care
News
Revolutionary Single-Dose Gene Therapy Offers New Hope for Adults with Hemophilia B
11/08/2024
A groundbreaking gene therapy for hemophilia B has shown remarkable success in reducing bleeding episodes and improving the quality of life for adult patients, according to a recent international phase III clinical trial.
A groundbreaking gene therapy for hemophilia B has shown remarkable success in reducing bleeding episodes and improving the quality of life for adult patients, according to a recent international phase III clinical trial.
A groundbreaking gene therapy...
11/08/2024
First Report Managed Care
News
Real-World Evidence Supports Efficacy and Safety of Selexipag in Patients With Pulmonary Arterial Hypertension
11/07/2024
Real-world data shows selexipag effectively improves functional class and risk category outcomes in patients with pulmonary arterial hypertension, regardless of maintenance dose.
Real-world data shows selexipag effectively improves functional class and risk category outcomes in patients with pulmonary arterial hypertension, regardless of maintenance dose.
Real-world data shows selexipag...
11/07/2024
First Report Managed Care
News
Clinical Predictors of One-Year Seizure Freedom After SLAH
11/06/2024
A study published in Annals of Clinical and Translational Neurology aimed to predict 1-year seizure freedom for patients undergoing stereotactic laser amygdalohippocampotomy (SLAH) for mesial temporal lobe epilepsy (MTLE) using a set of...
A study published in Annals of Clinical and Translational Neurology aimed to predict 1-year seizure freedom for patients undergoing stereotactic laser amygdalohippocampotomy (SLAH) for mesial temporal lobe epilepsy (MTLE) using a set of...
A study published in Annals of...
11/06/2024
First Report Managed Care
News
Efficacy and Outcomes of Neoadjuvant Immunotherapy in Lung Cancer
11/05/2024
A meta-analysis of 43 studies suggests that neoadjuvant chemoimmunotherapy may benefit patients with resectable NSCLC and low tumor PD-L1 levels for event-free survival, showing superior outcomes compared to neoadjuvant chemotherapy.
A meta-analysis of 43 studies suggests that neoadjuvant chemoimmunotherapy may benefit patients with resectable NSCLC and low tumor PD-L1 levels for event-free survival, showing superior outcomes compared to neoadjuvant chemotherapy.
A meta-analysis of 43 studies...
11/05/2024
First Report Managed Care
News
FDA Grants Accelerated Approval for Asciminib as First-Line Treatment in Ph+CML-CP
11/01/2024
Novartis received accelerated approval by the US Food and Drug Administration (FDA) for asciminib, a medication for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+CML-CP).
Novartis received accelerated approval by the US Food and Drug Administration (FDA) for asciminib, a medication for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+CML-CP).
Novartis received accelerated...
11/01/2024
First Report Managed Care
News
HHS Faces Legal Action From 10 Hospitals Over 2023 Medicare Advantage Rule and Reimbursement Calculations
10/30/2024
Ten hospitals sued the US Department of Health and Human Services (HHS), claiming that they were underpaid Medicare reimbursements for serving low-income patients.
Ten hospitals sued the US Department of Health and Human Services (HHS), claiming that they were underpaid Medicare reimbursements for serving low-income patients.
Ten hospitals sued the US...
10/30/2024
First Report Managed Care
News
Impact of Immune Checkpoint Inhibitors on Multiple Sclerosis Treatment Outcomes
10/29/2024
Relapses and progression of multiple sclerosis were rare in patients treated with immune checkpoint inhibitors, according to a study presented at the American Academy of Neurology 2024 Annual Meeting.
Relapses and progression of multiple sclerosis were rare in patients treated with immune checkpoint inhibitors, according to a study presented at the American Academy of Neurology 2024 Annual Meeting.
Relapses and progression of...
10/29/2024
First Report Managed Care

Advertisement

Advertisement

What's New?

News
RNAi Therapies Offer New Hope for Patients With Hereditary Transthyretin Amyloidosis
11/08/2024
RNA interference (RNAi)-based treatments for hereditary transthyretin amyloidosis (ATTR) have shown remarkable promise, offering new hope for patients with this rare but devastating genetic disorder.
RNA interference (RNAi)-based treatments for hereditary transthyretin amyloidosis (ATTR) have shown remarkable promise, offering new hope for patients with this rare but devastating genetic disorder.
RNA interference (RNAi)-based...
11/08/2024
First Report Managed Care
News
Experts Publish ATTRv Amyloidosis Recommendations for US Clinicians
10/09/2024
Citing a lack of guidance in the United States addressing hereditary transthyretin (ATTRv; v for variant) amyloidosis with polyneuropathy, a group of 7 neurologists with expertise in ATTRv amyloidosis published recommendations for...
Citing a lack of guidance in the United States addressing hereditary transthyretin (ATTRv; v for variant) amyloidosis with polyneuropathy, a group of 7 neurologists with expertise in ATTRv amyloidosis published recommendations for...
Citing a lack of guidance in the...
10/09/2024
First Report Managed Care
News
Treatment Provides Relief for Recurrent Acute Hepatic Porphyria Attacks
03/04/2022
Patients with recurrent attacks of acute hepatic porphyria had fewer attacks and less health care dependency after treatment with a double-stranded small interfering RNA.
Patients with recurrent attacks of acute hepatic porphyria had fewer attacks and less health care dependency after treatment with a double-stranded small interfering RNA.
Patients with recurrent attacks...
03/04/2022
First Report Managed Care
News
Treatment Proves Highly Effective for Primary Hyperoxaluria Type 1
02/17/2022
Eighteen months of follow-up data suggested lumasiran was highly effective in treating a patient with primary hyperoxaluria type 1, a rare genetic disease.
Eighteen months of follow-up data suggested lumasiran was highly effective in treating a patient with primary hyperoxaluria type 1, a rare genetic disease.
Eighteen months of follow-up...
02/17/2022
First Report Managed Care

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement